Supreme Announces Name Change and Provides Update

Supreme Pharmaceuticals Inc. ("Supreme" or the "Corporation") (TSX
VENTURE:SL)(OTCBB:SPRWF), formerly Supreme Resources Ltd., announces that it has
changed its name to Supreme Pharmaceuticals Inc. in conjunction with its recent
decision to pursue interests in pharmaceuticals and biomedical devices. The TSX
Venture Exchange has advised the Corporation that trading under the new name and
symbol "SL" will commence on March 14, 2014.


David Stadnyk, President & CEO, stated, "Although there is no certainty that a
transaction will be successfully concluded, the Corporation is in negotiations
to acquire an exclusive license agreement from an independent third party,
providing for the commercialization of patented technology focused on treating
gastrointestinal diseases and disorders. We are excited about diversifying
Supreme's focus to include multiple bio-technologies, with an initial focus on
obesity. The global obesity market is valued at over $1.6 trillion and the
Corporation hopes to make an announcement with regards to its continued
negotiations soon."


About Supreme Pharmaceuticals Inc.

Supreme Pharmaceuticals Inc., formerly Supreme Resources Ltd., holds advanced
base and precious metals projects located in producing mining districts of
British Columbia, Canada. It has recently taken the strategic decision to
acquire business interests in the life sciences field in order to increase
shareholder value. 


Website: www.supremepharmaceuticals.com. 

Further news will be forthcoming in the near future. 

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that
term is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release. 


Statements in this press release other than purely historical factual
information, including statements relating to revenues or profits, or the
Company's future plans and objectives, or expected sales, cash flows, and
capital expenditures constitute forward-looking statements. Forward-looking
statements are based on numerous assumptions and are subject to all of the risks
and uncertainties inherent in the Company's business, including risks inherent
in the technology history. There can be no assurance that such forward-looking
statements will prove to be accurate, as actual results and future events could
differ materially from those anticipated in such statements. Accordingly,
readers should not place undue reliance on such statements. Except in accordance
with applicable securities laws, the Company expressly disclaims any obligation
to update any forward-looking statements or forward-looking statements that are
incorporated by reference herein. This news release does not constitute an offer
to sell, or a solicitation of an offer to buy any of the Company's securities
set out herein in the United States, or to, or for the benefit or account of, a
U.S. Person or person in the United States.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Supreme Pharmaceuticals Inc.
David Stadnyk
President & CEO
403-210-8350
info@supremepharmaceuticals.com
www.supremepharmaceuticals.com

(TSXV:SL)
過去株価チャート
から 6 2024 まで 7 2024